Associate Professor

Pulmonology

Thomas Sisson works in the field of Pulmonology. He graduated from University of Michigan Medical School. He received awards:"CMS Meaningful Use Stage 1 Certification". Thomas Sisson has written publications. He has 31 publications published with PubMed. The lastest paper is: 'Milestones for Internal Medicine Sub-Interns.' He accepts Medicare payments and is registered with Medicare.gov.

Publications

---

• Inhibition of myocardin-related transcription factor/serum response factor signaling decreases Lung fibrosis and promotes mesenchymal cell apoptosis.
• Milestones for Internal Medicine Sub-Interns.
• Mechanosignaling through YAP and TAZ drives fibroblast activation and Fibrosis.
• Future Directions in Idiopathic Pulmonary Fibrosis Research: An NHLBI Workshop Report.
• Implicating Exudate Macrophages and Ly-6Chigh Monocytes in CCR2-Dependent Lung Fibrosis following Gene-Targeted Alveolar Injury.
• Animal Models of Fibrotic Lung Disease.
• X-Linked Inhibitor of Apoptosis Regulates Lung Fibroblast Resistance to Fas-mediated Apoptosis.
• Periostin promotes fibrosis and predicts progression in patients with Idiopathic Pulmonary Fibrosis.
• Increased survivin expression contributes to apoptosis-resistance in IPF fibroblasts.
• PAI-1 Promotes the Accumulation of Exudate Macrophages and Worsens Pulmonary Fibrosis Following Type II Alveolar Epithelial Cell Injury.
• Survivin expression induced by endothelin-1 promotes myofibroblast resistance to apoptosis.
• Plasmin overcomes resistance to prostaglandin E2 in fibrotic Lung fibroblasts by reorganizing protein kinase A signaling.
• The vitronectin binding function of PAI-1 exacerbates Lung fibrosis in mice.
• Macrophage-Specific Expression of Urokinase-Type Plasminogen Activator Promotes Skeletal Muscle Regeneration.
• Latent Infection by γherpesvirus stimulates profibrotic mediator release from multiple cell types.
• The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice.
• Targeted injury of type II alveolar epithelial cells induces Pulmonary fibrosis.
• Urokinase-type plasminogen activator increases hepatocyte growth factor activity required for skeletal muscle regeneration.
• Monocyte urokinase-type plasminogen activator up-regulation reduces thrombus size in a model of venous thrombosis.
• Inhalation of urokinase-type plasminogen activator reduces airway remodeling in a murine Asthma model.
• Plasminogen activation induced pericellular fibronectin proteolysis promotes fibroblast apoptosis.
• Plasminogen-mediated activation and release of hepatocyte growth factor from extracellular matrix.
• Expression of the reverse tetracycline-transactivator gene causes Emphysema-like changes in mice.
• Mice deficient in plasminogen activator inhibitor-1 have improved skeletal muscle regeneration.
• Plasminogen activator inhibitor-1 impairs alveolar epithelial repair by binding to vitronectin.
• Localization of plasminogen activator activity within normal and injured Lungs by in situ zymography.
• The plasminogen activation system reduces fibrosis in the Lung by a hepatocyte growth factor-dependent mechanism.
• Reduction in fibrotic tissue formation in mice genetically deficient in plasminogen activator inhibitor-1.
• A plasminogen activator inhibitor-1 promoter polymorphism and idiopathic Interstitial pneumonia.
• Inducible Lung-specific urokinase expression reduces fibrosis and mortality after Lung injury in mice.

Schools

---

• University Of Michigan Medical School

• University Of Mi Hosps and Health Ctrs

Procedures Preformed

---

• Bronchoscopy
• Thoracentesis
• Ventilation Management

Conditions Treated

---

• Acidosis
• Acute Pharyngitis
• Alkalosis
• Asthma
• View All

Doctors Specialties

---

• Critical Care Medicine
• Pulmonology

Accepted Insurances

---

• Choice Plus POS II
• Amerigroup (Wellpoint)
• Blue Card PPO
• Blue Cross Blue Shield of Illinois PPO
• Blue Care Network PCP Focus Network
• Group Employees PPO
• CareSource
• Cigna HMO
• Cigna PPO
• Great West Healthcare-Cigna PPO
• Open Access Plus
• Cofinity PPO
• Commercial Insurance Company
• CoreSource
• First Health (Coventry Health Care) PPO
• Golden Rule
• Health Alliance
• Choice Care PPO
• Medicaid
• Medicare MCR
• MultiPlan PPO
• PHCS Network PPO
• Mutual of Omaha
• NGS CoreSource
• PHP-Physicians Health Plan
• Priority PPO
• Tricare
• Choice Plus POS
• Options PPO
• United Healthcare

Awards

---

• CMS Meaningful Use Stage 1 Certification

Education

---

• University of Michigan Hospitals and Health Centers
• University of Michigan Medical School

Hospital

---

• University of Michigan Hospitals and Health Centers

Drug Facts

---

NPI NUMBER		1851473375
NPPES Provider LastName		SISSON
NPPES Provider FirstName		THOMAS
NPPES Provider ZIPCode		481095360
NPPES Provider State		MI
Specialty Description		Pulmonary Disease
Total Claim Count		555.0
Distinct Opioid Count		0.0
Opioid Claim Count		0.0
Percent Opioid Claims		0.0

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1851473375
Last Name Of The Provider	SISSON
First Name Of The Provider	THOMAS
View All

Similar Doctors

---

	Dr. Fernando J. Martinez, MD This Doctor is OpenDoctor Recommended.
	Dr. Christopher E. Morgan, MD This Doctor is OpenDoctor Recommended.
	Dr. Eric S. White, MD This Doctor is OpenDoctor Recommended.
	Dr. Elizabeth A. Belloli, MD This Doctor is OpenDoctor Recommended.
	Dr. James M. Beck, MD
	Dr. Rommel L. Sagana, MD This Doctor is OpenDoctor Recommended.
	Dr. Megan K. Dorsey, MD
	Dr. Victor R. Davila, MD
	Dr. Kristina E. Rudd, MD This Doctor is OpenDoctor Recommended.
	Dr. Tracy R. McMillan, MD
	Dr. Raju C. Reddy, MD
	Dr. Eleanore M. Yee, MD
	Dr. Carrie E. Harvey, MD This Doctor is OpenDoctor Recommended.
	Dr. Shilpa R. Patel, MD

---

Doctor Directory | TOS | twitter | FB | Angel | blog